J Cancer 2022; 13(9):2751-2756. doi:10.7150/jca.69811 This issue
1. ICMR-National Institute of Pathology, New Delhi, Safdarjung Hospital 110029, India.
2. Department of Urology, VMMC, Safdarjung Hospital 110029, India.
3. Dept of Laboratory Oncology, Dr. BRA-Institute Rotary Cancer Hospital, AIIMS, New Delhi, India.
4. Division of Cellular & Molecular Diagnostics, ICMR-National Institute of Cancer Prevention & Research, NOIDA, India.
Introduction: Urinary bladder cancer ranks the fourth most common cancer in men worldwide. Peroxiredoxins (PRDXs) are antioxidant enzymes that play an important role in cell proliferation and apoptosis. In the present study, we investigated whether PRDX 1 and 2 can be used as a urinary biomarker for surveillance of recurrence in urothelial cancer.
Materials and Methods: PRDX1 and PRDX2 expression levels were examined in 119 bladder tumor specimens by immunohistochemistry and in 150 urine samples (case: 100; healthy controls: 50) using ELISA and their association with recurrence and survival of patients was evaluated.
Results: Immunohistochemistry on FFPE tissue showed that both PRDX1 and PRDX2 were positive in bladder tumors and expressed in the cytoplasm and membrane of tumor cells. A significant elevation of urinary PRDX1 and PRDX2 concentration was found in bladder cancer patients and recurrent cases compared to the urine of healthy controls and primary bladder cancer patients (p<0.001 & p<0.01) respectively. However, the concentration of both proteins was not found associated with survival.
Conclusion: Elevated urinary PRDX1 and PRDX2 in bladder cancer patients was found to be associated with recurrence and the estimation of urinary PRDX1 and PRDX2 during follow-up may help to extend the period between cystoscopies in patient follow-up.
Keywords: Bladder cancer, Urinary PRDX1, and PRDX2